 Geoffrey Nunns
Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Coagulation Disorders | 9 | 2020 | 198 | 1.390 |
Why?
| | Thrombelastography | 14 | 2020 | 192 | 1.090 |
Why?
| | Wounds and Injuries | 15 | 2020 | 962 | 1.090 |
Why?
| | Peritoneal Neoplasms | 4 | 2026 | 104 | 0.820 |
Why?
| | Shock, Hemorrhagic | 4 | 2018 | 199 | 0.790 |
Why?
| | Bronchopulmonary Sequestration | 1 | 2020 | 9 | 0.650 |
Why?
| | Stomach Neoplasms | 3 | 2026 | 128 | 0.600 |
Why?
| | Biomarkers, Tumor | 4 | 2026 | 1329 | 0.560 |
Why?
| | Hemorrhage | 3 | 2018 | 822 | 0.560 |
Why?
| | 5-Lipoxygenase-Activating Proteins | 1 | 2018 | 4 | 0.550 |
Why?
| | Fibrinogen | 3 | 2019 | 180 | 0.550 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2018 | 37 | 0.540 |
Why?
| | Fibrinolysis | 5 | 2020 | 164 | 0.530 |
Why?
| | Blood Coagulation Tests | 1 | 2017 | 72 | 0.510 |
Why?
| | Blood Transfusion | 4 | 2019 | 409 | 0.500 |
Why?
| | Thrombophilia | 1 | 2017 | 89 | 0.500 |
Why?
| | Cytoreduction Surgical Procedures | 3 | 2026 | 69 | 0.480 |
Why?
| | Blood Component Transfusion | 3 | 2020 | 102 | 0.430 |
Why?
| | Acute Lung Injury | 1 | 2018 | 307 | 0.420 |
Why?
| | Hyperthermia, Induced | 2 | 2026 | 120 | 0.400 |
Why?
| | Blood Coagulation | 4 | 2019 | 274 | 0.390 |
Why?
| | Pancreatic Neoplasms | 3 | 2025 | 928 | 0.370 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 599 | 0.340 |
Why?
| | Succinic Acid | 3 | 2020 | 46 | 0.330 |
Why?
| | Resuscitation | 5 | 2020 | 312 | 0.320 |
Why?
| | Adenocarcinoma | 3 | 2026 | 926 | 0.300 |
Why?
| | Plasma | 3 | 2020 | 223 | 0.280 |
Why?
| | Renal Dialysis | 2 | 2026 | 466 | 0.270 |
Why?
| | Plasminogen Activator Inhibitor 1 | 2 | 2018 | 85 | 0.270 |
Why?
| | Neuroendocrine Tumors | 2 | 2025 | 119 | 0.250 |
Why?
| | Colorectal Neoplasms | 2 | 2026 | 868 | 0.250 |
Why?
| | Microsatellite Instability | 1 | 2026 | 55 | 0.230 |
Why?
| | Esophagogastric Junction | 1 | 2026 | 55 | 0.230 |
Why?
| | Tissue Plasminogen Activator | 4 | 2020 | 248 | 0.230 |
Why?
| | Neoadjuvant Therapy | 2 | 2026 | 467 | 0.230 |
Why?
| | Gene Fusion | 1 | 2025 | 30 | 0.230 |
Why?
| | Neoplasms, Second Primary | 1 | 2026 | 102 | 0.220 |
Why?
| | Pancreaticoduodenectomy | 1 | 2026 | 137 | 0.220 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2025 | 178 | 0.210 |
Why?
| | Metabolome | 2 | 2018 | 391 | 0.210 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2025 | 254 | 0.210 |
Why?
| | Paclitaxel | 1 | 2025 | 259 | 0.210 |
Why?
| | Bile Duct Neoplasms | 1 | 2026 | 131 | 0.210 |
Why?
| | Gene Frequency | 1 | 2025 | 489 | 0.210 |
Why?
| | Prognosis | 8 | 2026 | 4330 | 0.210 |
Why?
| | Sequence Analysis, RNA | 1 | 2026 | 442 | 0.200 |
Why?
| | Survival Rate | 5 | 2026 | 2094 | 0.200 |
Why?
| | Cholestasis | 1 | 2026 | 214 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2025 | 171 | 0.190 |
Why?
| | Male | 24 | 2026 | 73011 | 0.190 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2026 | 534 | 0.180 |
Why?
| | Rats, Sprague-Dawley | 5 | 2019 | 2525 | 0.180 |
Why?
| | Middle Aged | 15 | 2026 | 36309 | 0.180 |
Why?
| | Patient Selection | 2 | 2024 | 739 | 0.180 |
Why?
| | Metabolomics | 2 | 2018 | 733 | 0.180 |
Why?
| | Esophageal Neoplasms | 1 | 2026 | 348 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2025 | 293 | 0.180 |
Why?
| | Robotic Surgical Procedures | 1 | 2024 | 185 | 0.170 |
Why?
| | Adult | 17 | 2026 | 40881 | 0.170 |
Why?
| | Pancreatectomy | 1 | 2024 | 289 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2026 | 1969 | 0.170 |
Why?
| | Humans | 30 | 2026 | 145783 | 0.160 |
Why?
| | alpha-2-Antiplasmin | 1 | 2020 | 3 | 0.160 |
Why?
| | Early Detection of Cancer | 1 | 2026 | 486 | 0.160 |
Why?
| | Saline Solution, Hypertonic | 1 | 2019 | 43 | 0.150 |
Why?
| | Antifibrinolytic Agents | 2 | 2018 | 64 | 0.150 |
Why?
| | Lactic Acid | 2 | 2018 | 295 | 0.150 |
Why?
| | Intracranial Hypertension | 1 | 2019 | 42 | 0.150 |
Why?
| | Colorado | 3 | 2018 | 4556 | 0.150 |
Why?
| | Alcoholic Intoxication | 1 | 2020 | 76 | 0.140 |
Why?
| | Cytoplasmic Granules | 1 | 2018 | 60 | 0.140 |
Why?
| | Leukotrienes | 1 | 2018 | 28 | 0.140 |
Why?
| | Practice Guidelines as Topic | 1 | 2026 | 1582 | 0.130 |
Why?
| | Thrombin | 1 | 2018 | 172 | 0.130 |
Why?
| | Combined Modality Therapy | 3 | 2026 | 1271 | 0.130 |
Why?
| | Adenosine Diphosphate | 1 | 2017 | 83 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2019 | 4568 | 0.130 |
Why?
| | Refrigeration | 1 | 2017 | 11 | 0.130 |
Why?
| | Female | 17 | 2026 | 79045 | 0.130 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2017 | 92 | 0.130 |
Why?
| | Hemostatics | 1 | 2017 | 64 | 0.120 |
Why?
| | Platelet Transfusion | 1 | 2017 | 77 | 0.120 |
Why?
| | Tranexamic Acid | 1 | 2017 | 59 | 0.120 |
Why?
| | Lung | 2 | 2020 | 4116 | 0.120 |
Why?
| | Case-Control Studies | 3 | 2019 | 3634 | 0.120 |
Why?
| | Reperfusion Injury | 1 | 2018 | 292 | 0.120 |
Why?
| | Models, Animal | 1 | 2017 | 392 | 0.110 |
Why?
| | Erythrocyte Transfusion | 1 | 2017 | 225 | 0.110 |
Why?
| | Rats | 3 | 2018 | 5585 | 0.110 |
Why?
| | Swine | 4 | 2018 | 826 | 0.110 |
Why?
| | Neutrophils | 1 | 2020 | 1127 | 0.110 |
Why?
| | Animals | 8 | 2020 | 38102 | 0.100 |
Why?
| | Mutation | 1 | 2025 | 4090 | 0.100 |
Why?
| | Follow-Up Studies | 4 | 2026 | 5428 | 0.100 |
Why?
| | Phenotype | 2 | 2019 | 3170 | 0.100 |
Why?
| | Hospital Mortality | 1 | 2017 | 1038 | 0.090 |
Why?
| | Aged | 7 | 2026 | 26217 | 0.090 |
Why?
| | Prospective Studies | 5 | 2026 | 8078 | 0.090 |
Why?
| | Risk Assessment | 2 | 2018 | 3752 | 0.080 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2017 | 668 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2026 | 17330 | 0.080 |
Why?
| | Liver | 1 | 2018 | 1899 | 0.080 |
Why?
| | Partial Thromboplastin Time | 2 | 2019 | 53 | 0.070 |
Why?
| | International Normalized Ratio | 2 | 2019 | 55 | 0.070 |
Why?
| | Trauma Severity Indices | 2 | 2020 | 115 | 0.070 |
Why?
| | Healthy Volunteers | 2 | 2020 | 219 | 0.070 |
Why?
| | Cohort Studies | 1 | 2018 | 6033 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2026 | 2123 | 0.060 |
Why?
| | Computer Simulation | 1 | 2011 | 1003 | 0.060 |
Why?
| | Databases, Factual | 2 | 2026 | 1491 | 0.060 |
Why?
| | ROC Curve | 2 | 2018 | 618 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 849 | 0.060 |
Why?
| | Infusions, Parenteral | 1 | 2025 | 48 | 0.060 |
Why?
| | Constriction, Pathologic | 1 | 2026 | 249 | 0.050 |
Why?
| | Insulinoma | 1 | 2024 | 29 | 0.050 |
Why?
| | Chemotherapy, Cancer, Regional Perfusion | 1 | 2024 | 30 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2026 | 427 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2024 | 40 | 0.050 |
Why?
| | Gastrectomy | 1 | 2025 | 166 | 0.050 |
Why?
| | Propensity Score | 1 | 2026 | 377 | 0.050 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2026 | 223 | 0.050 |
Why?
| | Models, Biological | 1 | 2011 | 1764 | 0.050 |
Why?
| | Biopsy | 1 | 2026 | 1082 | 0.050 |
Why?
| | Biomarkers | 3 | 2018 | 4302 | 0.040 |
Why?
| | Coagulation Protein Disorders | 1 | 2019 | 3 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2019 | 19 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1049 | 0.040 |
Why?
| | Kaolin | 1 | 2018 | 7 | 0.040 |
Why?
| | Transcriptome | 1 | 2025 | 1042 | 0.040 |
Why?
| | Blood Coagulation Factors | 1 | 2019 | 71 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2025 | 1777 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2018 | 125 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 332 | 0.030 |
Why?
| | Platelet Function Tests | 1 | 2017 | 35 | 0.030 |
Why?
| | Crush Injuries | 1 | 2017 | 14 | 0.030 |
Why?
| | Hemostatic Techniques | 1 | 2018 | 52 | 0.030 |
Why?
| | Swine, Miniature | 1 | 2017 | 89 | 0.030 |
Why?
| | Time Factors | 2 | 2019 | 7134 | 0.030 |
Why?
| | Patient Care Planning | 1 | 2018 | 170 | 0.030 |
Why?
| | Primates | 1 | 2018 | 133 | 0.030 |
Why?
| | Femoral Fractures | 1 | 2017 | 84 | 0.030 |
Why?
| | Glycolysis | 1 | 2018 | 340 | 0.030 |
Why?
| | Trauma Centers | 1 | 2019 | 466 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 592 | 0.030 |
Why?
| | Wounds, Nonpenetrating | 1 | 2019 | 321 | 0.030 |
Why?
| | Injury Severity Score | 1 | 2017 | 599 | 0.030 |
Why?
| | Blood Platelets | 1 | 2018 | 379 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 876 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2018 | 1069 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2139 | 0.030 |
Why?
| | Intestines | 1 | 2017 | 354 | 0.030 |
Why?
| | Hyperglycemia | 1 | 2018 | 380 | 0.030 |
Why?
| | Brain Injuries, Traumatic | 1 | 2019 | 453 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2026 | 2977 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2017 | 935 | 0.020 |
Why?
| | Young Adult | 2 | 2019 | 14254 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1188 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2026 | 11794 | 0.020 |
Why?
| | Computational Biology | 1 | 2011 | 669 | 0.010 |
Why?
| | Software | 1 | 2011 | 680 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10919 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22577 | 0.010 |
Why?
| | Child | 1 | 2019 | 22740 | 0.010 |
Why?
|
|
Nunns's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|